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ARTICLE
Phosphoserine Aminotransferase Deﬁciency: A Novel Disorder
of the Serine Biosynthesis Pathway
Claire E. Hart, Valerie Race, Younes Achouri, Elsa Wiame, Mark Sharrard, Simon E. Olpin,
Jennifer Watkinson, James R. Bonham, Jaak Jaeken, Gert Matthijs, and Emile Van Schaftingen
We present the ﬁrst two identiﬁed cases of phosphoserine aminotransferase deﬁciency. This disorder of serine biosynthesis
has been identiﬁed in two siblings who showed low concentrations of serine and glycine in plasma and cerebrospinal
ﬂuid. Clinically, the index patient presented with intractable seizures, acquired microcephaly, hypertonia, and psycho-
motor retardation and died at age 7 mo despite supplementation with serine (500 mg/kg/d) and glycine (200 mg/kg/d)
from age 11 wk. The younger sibling received treatment from birth, which led to a normal outcome at age 3 years.
Measurement of phosphoserine aminotransferase activity in cultured ﬁbroblasts in the index patient was inconclusive,
but mutational analysis revealed compound heterozygosity for two mutations in the PSAT1 gene—one frameshift mu-
tation (c.delG107) and one missense mutation (c.299ArC [p.Asp100Ala])—in both siblings. Expression studies of the
p.Asp100Ala mutant protein revealed a Vmax of only 15% of that of the wild-type protein.
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Disorders due to deﬁciency of the ﬁrst and third enzymes
of the three-enzyme serine biosynthesis pathwayhavepre-
viously been characterized. 3-Phosphoglycerate dehydro-
genase (encoded by PHGDH) deﬁciency (MIM601815)was
the ﬁrst serine-biosynthesis disorder to be reported (in
1996 by Jaeken and colleagues), and several patients have
subsequently been identiﬁed.1–3 This is a severe neurolog-
ical disorder presenting typically with congenital micro-
cephaly, seizures, psychomotor retardation, and spastic te-
traparesis. Phosphoserine phosphatase (encoded by PSPH)
deﬁciency (MIM 172480) has been identiﬁed to date in
only one patient, and the clinical consequences of this
enzyme deﬁciency are not clear because of the concom-
itant Williams syndrome in this patient.4,5 Patients with
these disorders have received treatment with supplemen-
tal serine and glycine, which had varying degrees of
success.1,2,6 Patients with a deﬁciency of phosphoserine
aminotransferase (EC 2.6.1.52), the second enzyme in the
pathway, have not been reported previously.
L-serine may be derived from four possible sources: di-
etary intake, degradation of protein and phospholipids,
biosynthesis from the glycolytic-pathway intermediate
3-phosphoglycerate via the so-called phosphorylated
pathway, or glycine.7 The “nonphosphorylated pathway,”
involving D-glycerate and hydroxypyruvate as interme-
diates, is now known to be involved in serine degradation
(see the “Discussion” section). Serine is a nonessential
amino acid, and it is now clear that dietary sources are
insufﬁcient to meet all requirements.1,2,8 The poor trans-
port of serine across the blood-brain barrier means that
the brain, in particular, appears to be reliant on local de
novo synthesis from 3-phosphoglycerate.9 Serine is re-
quired for both brain development and brain function;
therefore, neurological symptoms predominate in the ser-
ine-biosynthesis disorders.1–4,7 Glycine can be synthesized
directly from serine, and vice versa, by the action of serine
hydroxymethyl transferase, which explains why serine-




This study was approved by the ethical committee of the Faculty
ofMedicine, Universite´ Catholique de Louvain. Informedconsent
was obtained from the parents of the investigated family.
Patient 1 is a male, the second child of healthy, unrelated par-
ents of British origin. He was born at term by cesarean delivery
because of a low-lying placenta. He was healthy at birth, with
head circumference and weight in the 9th percentile. At age 2
wk, he was admitted to the hospital with poor feeding and cy-
anotic episodes thought to be related to an upper respiratory tract
infection. At age 7 wk, he was experiencing jerking movements
and posturing. At age 9 wk, he presented with severe, intractable
seizures and slight hypertonia. His head circumferencewas !0.4th
percentile, whereas his weight was in the 2nd percentile. His sei-
zures could not be controlled, despite multiple-anticonvulsants
therapy including clonazepam, phenytoin, and paraldehyde, and
he was transferred to the regional pediatric intensive care unit,
received mechanical ventilation, and was sedated with thiopen-
tone. Pyridoxine at 120 mg/d was given from age 10 wk but had
no observable effect. Extensive biochemical investigations re-
vealed no abnormalities, with the exception of low plasma and
cerebrospinal ﬂuid (CSF) concentrations of serine and glycine (ta-
ble 1). Cranial imaging showed generalized atrophy, a hypoplastic
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Table 1. Plasma and CSF Serine and Glycine Results for






Serine Glycine Serine Glycine
1 51 (60–300) 121 (140–420) 18 (35–80) !1 (3–10)
2 30 (50–350) 110 (200–600) 5 (35–80) !1 (3–10)
NOTE.—Plasma and CSF amino acids were measured by ion-exchange
chromatography with ninhydrin detection.
a The normal range is shown in parentheses.
Table 2. Primers and PCR Conditions Used
for Ampliﬁcation of Exons of PHGDH,
PSAT1, and PSPH
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 1. MRI scans from patient 1 showing generalized atrophy and a hypoplastic cerebellar vermis
cerebellar vermis, and poor white-matter development (ﬁg. 1). An
electroencephalogram was consistent with multifocal seizure ac-
tivity. Treatment was begun with serine (500 mg/kg/d) and gly-
cine (200 mg/kg/d) at age 11 wk, which normalized plasma and
CSF concentrations. The clinical effect was limited, with only a
marginal improvement in seizure control and responsiveness. Se-
vere seizure episodes that required admission to the intensive care
unit continued, the hypertonia worsened, and eventually the pa-
tient died at age 7 mo.
Patient 2 is the younger sister of patient 1. She was born at
term by cesarean delivery because of the previous cesarean de-
livery. She was healthy at birth, with head circumference and
weight in the 9th percentile. Prenatal monitoring had showed
normal fetal development. However, a plasma sample taken at
age 2 h revealed low concentrations of serine and glycine, which
was also found in a CSF sample (table 1). Supplementation with
serine (500mg/kg/d) and glycine (200mg/kg/d)was begunwithin
the ﬁrst 24 h of life. Cranial ultrasonography at age 3 wk and a
magnetic resonance imaging (MRI) scan at age 4 mo showed no
abnormalities. Her head circumference increased from the 9th
percentile at birth to the 50th–75th percentile by age 18 wk, as
did her weight. She experienced one apneic episode at age 2 wk
but was otherwise asymptomatic and has remained asymptom-
atic. Her growth and development are normal at age 3 years.
Mutational Analysis
Genomic DNA was extracted from ﬁbroblasts according to stan-
dard procedures. All exons of PHGDH (exons 1–12) and PSAT1
(exons 1–9) and the coding exons of PSPH (exons 4–8) were PCR
ampliﬁed using 0.2–0.5 mM of forward and reverse primers (Eu-
rogentec) (table 2) with 75–300 ng of genomic DNA template.
These (50 ml) reactions were performed using the indicated DNA
polymerase in the recommended buffer, 0.2 mM nucleotide tri-
phosphates and, where indicated, betaine (Sigma) (table 2). Bio-
tools DNA polymerase was from Biotools, Optimase was from
Transgenomic, and Taq polymerase was from Roche. The PCR
ampliﬁcations started with an initial denaturation step at 95C
for 3–5 min, followed by 35 cycles for 0.5 min at 95C, 0.5–1min
at the annealing temperature (table 2), and 1 min at 72C. The
ﬁnal extension step at 72C lasted 5–35 min. PCR products were
puriﬁed and were sequenced directly on both strands by use of
either an ABI 3100 Genetic Analyzer (Applied Biosystems) or a
CEQ2000 sequencer (Beckman).
Expression of Wild-Type and Mutated Phosphoserine
Aminotransferase
Human recombinant wild-type phosphoserine aminotransferase
(i.e., the full length cDNA, designated “PSATb” by Baek et al.10)
and PSAT-D100A were produced as fusion proteins with an N-
terminal polyHis tag. The coding sequence (AY131232) was am-
pliﬁed by PCR with the use of Pwo DNA polymerase and two
oligonucleotides (5′-GCCATATGGACGCCCCCAGGCAGG-3′,
containing an NdeI restriction site, and 5′-CGGATCCTCATAGCT-
GATGCATCTCCAAAAAT-3′, containing a BamHI restriction site;
restriction sites are underlined) by use of human ﬁbroblast cDNA
as matrix. The ampliﬁed fragment was cloned into pBluescript
restricted with EcoRV, to produce the plasmid pBS-PSAT. The cod-
ing sequence was excised from this plasmid by digestion with
NdeI and BamHI and was ligated into the NdeI and BamHI sites
of the expression vector pET15b, to produce the expression plas-
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Controls 29.5  2.7a 2.0  0.3b 1.7  0.2c
Patient 1 70 0.9 2.4
a Mean  SEM for 15 control subjects.
b Mean  SEM for 9 control subjects.
c Mean  SEM for 14 control subjects.
Figure 2. Mutational analysis of patients 1 and 2. A heterozygous 1-bp deletion in exon 2 and a heterozygous ArC transversion in
exon 4, leading to the replacement of the Asp at position 100 with an Ala, were found in the PSAT1 gene. Both patients were also
heterozygous for a silent polymorphism in exon 4. In the panels corresponding to exon 2, only the wild-type sequence is shown below
each chromatogram.
mid pET15-PSAT. The Asp100Ala point mutation was introduced
into pBS-PSAT by site-directed mutagenesis with the use of the
Quick Change kit (Stratagene). An NdeI restriction-enzyme site
was also introduced into the DNA, providing a rapid method to
screen for thismutation. The forward primer used formutagenesis
was 5′-GCAGGAAGGTGTGCGGCATATGTGGTGACAGGAG-3′
(the nucleotide change is in italics and the resulting NdeI site is
underlined). The reverse primer was complementary to the for-
ward primer. An NheI-BamHI fragment containing the mutation
was exchanged for the same restriction fragment in the wild-type
expression vector (pET15-PSAT). To produce the recombinant en-
zyme, Escherichia coli BL21 cells11 were transformed with the ex-
pression vector and were grown in 0.5 liter of LB medium at 37C
until absorbance at 600 nm reached 0.6 U. The culture was then
quenched for 30 min on ice. Expression of the recombinant pro-
tein was induced by addition of 1 mM isopropyl thiogalactoside
for 16 h at 18C. Cells were collected by centrifugation and were
lysed in 10 ml of 100 mM Tris (pH 8) containing 5 mg/ml leu-
peptin, 5 mg/ml antipain, 0.25 mM phenylmethylsulfonyl ﬂuo-
ride, 25 mM KCl, and 1 mg/ml lysozyme. The lysate was centri-
fuged at 20,000 g for 30 min at 4C. The protein was puriﬁed over
a 1-ml His-trapFF afﬁnity column.
Enzyme Assays
Enzyme assays were performed on ﬁbroblasts by use of methods
described elsewhere.1 The activity of recombinant wild-type and
mutated phosphoserine aminotransferase was measured spectro-
photometrically at 340 nm by measuring the disappearance of
reduced nicotinamide adenine dinucleotide (NADH) in an assay
mixture (1 ml) containing, unless otherwise indicated, 25 mM
HEPES (pH 7.1), 5 mM pyridoxal phosphate, 1 mM MgCl2, 0.5
mM a-ketoglutarate, 25 mM KCl, 150 mM NADH, and 10 mg/ml
recombinant rat liver 3-phosphoglycerate dehydrogenase.12 The
reaction was run at 30C and was initiated by the addition of 0.5
mM phosphoserine.
Results
3-Phosphoglycerate dehydrogenase and phosphoserine
phosphatase activity in ﬁbroblasts of patient 1 were not
decreased compared with that in controls (table 3). Phos-
phoserine aminotransferase activity was low in compari-
son with that in controls but not sufﬁciently to conclude
that there is a deﬁciency disorder. At this stage, because
of the failure of enzyme assays to reveal a diagnosis despite
clear biochemical and clinical indication of a serine/gly-
cine deﬁciency disorder, the decision was made to begin
mutational analysis. No mutations were identiﬁed in the
PHGDH and PSPH genes, whereas both affected siblings
were found to be compound heterozygotes for mutations
in the PSAT1 gene. They have one frameshift mutation,
c.delG107 in exon 2, and one missense mutation,
c.299ArC (p.Asp100Ala) in exon 4 (ﬁg. 2). Analysis of
DNA from the parents indicated that the frameshift mu-
tation was inherited from the father and that themissense
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Figure 3. Alignment of Homo sapiens (Hsap) and E. coli (Eco1)
phosphoserine aminotransferase. Identical residues are indicated
in black. The effect of the mutations found in the patients on the
amino acid sequence is indicated above the alignment. The as-
paragine residue (Ser138) that interacts with the side chain of
Asp100 in E. coli phosphoserine aminotransferase is highlighted
in gray.
Figure 4. Model of the position of Asp93 (equivalent of Asp100)
and the neighboring residue Ser138 (equivalent of Asn143) in E.
coli phosphoserine aminotransferase. The image was drawn with
PyMOL software by use of the E. coli phosphoserine aminotrans-
ferase coordinates (Protein Data Bank code 1BJN).10
mutation was inherited from the mother. The missense
mutationwas foundnext to a known silent polymorphism
in exon 4 (c.297GrT [p.Ala99Ala]; rs3739474), which
both children inherited from their mother. The missense
mutation was not found in 119 controls by denaturing
high-performance liquid chromatography and sequenc-
ing, whereas the polymorphism was found with a G allele
frequency of 0.65 and was consistent with Hardy-Wein-
berg equilibrium.
Multiple sequence alignments show that Asp100 is well
conserved. From the three-dimensional structure of E. coli
phosphoserine aminotransferase,13 which shares 46% se-
quence identity with its human homologue (ﬁg. 3), it
turns out that the residue in the equivalent position in
the bacterial sequence (Asp93) is buried, with its side chain
hydrogen bonded to the nitrogen and the side-chain hy-
droxyl group of Ser138 (ﬁg. 4). It is likely that, in the
human sequence, Asp100 forms bonds with the aspara-
gine (Asn143) similar to those between Asp 93 and Ser138
of the E. coli sequence. Replacement of Asp100 by an
alanine will disrupt the hydrogen bonds that associate
Asp100 with the neighboring loop.
To test the effect of the Asp100Ala mutation, we pre-
pared bacterial expression vectors that encode wild-type
and mutated human phosphoserine aminotransferases as
fusion proteins with an N-terminal His tag. Both the wild-
type protein and the Asp100Ala mutant were expressed
in E. coli. Extracts were prepared, and the recombinant
proteins were puriﬁed by metal-afﬁnity chromatography.
These experiments showed that the yield of soluble phos-
phoserine aminotransferase was consistently much lower
(by ∼10-fold) for the mutant protein than for the wild-
type protein (ﬁg. 5). This was observed irrespective of the
temperature at which the protein was expressed (18C or
37C). The kinetic properties of both puriﬁed proteins
were determined. The main difference found was that the
Vmax of the puriﬁed mutated protein (expressed per mg of
puriﬁed protein) was ∼15% of theVmax of the puriﬁedwild-
type protein ( mmol/min/mg of protein). NoV p 1.35max
difference in Km for phosphoserine (5 mM in both cases)
was noticed.
Discussion
The ﬁrst two individuals with phosphoserine aminotrans-
ferase deﬁciency have been identiﬁed and described. This
disorder is characterized biochemically by low plasma and
CSF concentrations of serine and glycine and clinically by
intractable seizures, acquired microcephaly, hypertonia,
and psychomotor retardation. Outcome is poor once the
individual becomes symptomatic, but the younger sibling
of the index patient has received successful treatmentwith
serine and glycine supplementation that began at birth.
The biochemical and clinical features of phosphoserine
aminotransferase deﬁciency are similar to those of 3-phos-
phoglycerate dehydrogenase deﬁciency. Importantly, in
keeping with the other serine/glycine deﬁciency disorders,
these two patients have a partial enzyme deﬁciency. This
is not unexpected, given that, in the mouse Phgdh knock-
out model, complete enzyme deﬁciency is incompatible
with life at the fetal stage.14
Although the clinical presentation of patient 1 is very
similar to that of patients with 3-phosphoglycerate de-
hydrogenase deﬁciency, there are some important differ-
ences. First, neither patient 1 nor patient 2 (who did not
receive treatment until birth) displayed congenital micro-
cephaly. On ﬁrst consideration, this may suggest a less
severe disorder with a greater bioavailability of serine and
glycine, despite the equally low plasma and CSF levels.
However, once patient 1 became symptomatic, he dis-
played symptoms that can be considered signiﬁcantly
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Figure 5. Puriﬁcation of recombinant human wild-type and
Asp100Ala mutant phosphoserine aminotransferase by chromatog-
raphy on metal-afﬁnity column. Bacterial extracts were loaded onto
a 1-ml His-trapFF afﬁnity column (not shown), which was washed
with buffer. Phosphoserine aminotransferase was eluted with a
linear imidazole gradient. Fractions were collected as indicated.
Samples from the indicated fractions were analyzed by SDS-PAGE.
more severe than those displayed by the patients with 3-
phosphoglycerate dehydrogenase deﬁciency. With con-
genital microcephaly and severe developmental delay, the
dehydrogenase-deﬁcient patients may not display overt
seizure activity until ages 6 mo to 1 year, and long-term
survival is the norm.6 In addition, they display a much
greater clinical response to serine and glycine supplemen-
tation, with seizures being much better controlled or even
abolished. Patient 1, however, showed little response to
treatment with serine and glycine supplementation, de-
spite normalization of plasma and CSF levels, and died at
age 7 mo. The severity of the outcome in this patient is
possibly due to brain damage suffered during a seizure
episode early in the clinical course.
The experience with patient 2 conﬁrms the observation
of de Koning et al. that serine-deﬁciency disorders can be
treated successfully if treatment is begun before symptoms
appear.15 In the case of patients with 3-phosphoglycerate
dehydrogenase deﬁciency, this requires prenatal treat-
ment. Given that the patients with phosphoserine trans-
aminase deﬁciency appear to be just as deﬁcient in serine
and glycine as are the patients with 3-phosphoglycerate
dehydrogenase deﬁciency, the fact that neither patient
was overtly symptomatic at birth suggests that the trans-
aminase deﬁciency was better tolerated during prenatal
life than was the dehydrogenase deﬁciency. Another pos-
sibility is that, because of other genetic or external dietary
factors, there was a better supply of serine and glycine to
the fetus from thismother, although, given the poor trans-
portation of serine and glycine across the blood-brain bar-
rier and the supraphysiological doses of serine and glycine
required to treat this condition, it is hard to envisage a
mechanism that would make such a substantial difference
in the availability of these amino acids to the fetal
brain.9,15,16 Until additional, unrelated patients are iden-
tiﬁed, it is not possible to know whether rapidly acquired,
rather than congenital, microcephaly is the norm in phos-
phoserine aminotransferase deﬁciency. It is clear from pa-
tient 1 that, very shortly after birth, at a time when brain
development is still a very active process, the supply of
serine and glycine became insufﬁcient to meet require-
ments, and irreversible damage was sustained.
Previous studies have indicated that 3-phosphoglycerate
dehydrogenase and phosphoserine aminotransferase both
catalyze reactions that are close to thermodynamic equi-
librium.17 It is therefore unlikely that 3-phosphohydrox-
ypyruvate accumulates in phosphoserine aminotransfer-
ase deﬁciency, particularly because 3-phosphoglycerate is
easily converted to pyruvate (and hence to other metab-
olites) by glycolysis. The lack of serine, the end product
of the pathway, appears, therefore, to be the major mech-
anism for causation of the clinical features in this disorder,
as further indicated by the normal development of patient
2. This is in contrast to disorders of amino acid catabolic
pathways. They typically lead to accumulation of an
amino acid, an intermediate of the catabolic pathway, or
a product thereof, which, in many instances (e.g., phe-
nylalanine in phenylketonuria18 and succinylacetone in
hypertyrosinemia type I19) exert toxic effects. The mech-
anisms by which serine deﬁciency leads to pathological
consequences are unknown, but they probably involve
decreased synthesis of serine-derived compounds, such
as membrane lipids (phospholipids or ceramides) or the
neuromodulators glycine or D-serine. D-serine, which is
formed through isomerization of L-serine by serine race-
mase, is known to be decreased in the CSF of children
with 3-phosphoglycerate dehydrogenase deﬁciency.8 It is
likely that this is also the case for patients with phos-
phoserine aminotransferase deﬁciency, though this point
is not speciﬁcally addressed in the present study. Alter-
natively, reduced availability of serine may result in de-
ﬁciency of 1-carbon groups that are essential for purine
and pyrimidine metabolism.7
These cases highlight the problem of identifying pa-
tients with serine/glycine-deﬁciency disorders and the im-
portance of making the diagnosis, given that subsequent
affected siblings can receive very effective treatment. The
plasma serine and glycine concentrations of patient 1were
only marginally below the lower limit of the reference
range and could easily have been overlooked. This em-
phasizes the importance of measuring serine and glycine
in CSF, as well as in plasma.1 Enzymatic conﬁrmation of
a diagnosis, once a serine-biosynthesis disorder is sus-
pected, is also problematic. Assays of all three enzymes in
the pathway in patient 1 did not reveal a clear enzyme
deﬁciency, necessitating mutational analysis to uncover
the diagnosis. The decrease in the phosphoserine ami-
notransferase activity found in ﬁbroblasts of patient 1 was
only ∼50%, whereas a much larger decrease would be ex-
pected from the molecular studies, given that the patient
was compound heterozygous for a null mutation and an
amino acid substitution that decreases the enzymatic ac-
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tivity of recombinant phosphoserine aminotransferase by
at least about sixfold. These ﬁndings suggest that the en-
zymatic assay used in ﬁbroblasts is not entirely speciﬁc
for phosphoserine aminotransferase or that compensatory
mechanisms lead to increased expression of the mutated
enzyme. It is therefore advisable to look for mutations in
the genes encoding the three enzymes of the serine-bio-
synthesis pathway in patients with serine deﬁciency.
It is now generally accepted that serine biosynthesis
from 3-phosphoglycerate proceeds via the phosphorylated
pathway, involving 3-phosphohydroxypyruvate and
phosphoserine as intermediates, and that the nonphos-
phorylated pathway, involving hydroxypyruvate and D-
glycerate as intermediates, is used for serine degradation
in humans.20 Some species use serine dehydratase to de-
grade serine. Phosphoserine phosphatase catalyzes an ir-
reversible reaction, and there is no kinase that acts on free
serine, which indicates that the phosphorylated pathway
can serve only to make serine. Reciprocally, the existence
of a kinase that converts D-glycerate to 2-phosphoglycer-
ate and the ﬁnding that D-glycerate dehydrogenase shows
an ∼200-fold higher afﬁnity for NADP (which is essentially
present in reduced form) than for NAD21 make it likely
that the nonphosphorylated pathway proceeds unidirec-
tionally from serine to 2-phosphoglycerate. Inborn errors
of serine metabolism strengthen this view, because a de-
ﬁciency in any of the three enzymes of the phosphoryl-
ated pathway leads to serine and glycine deﬁciency. Fur-
thermore, deﬁciency of D-glycerate dehydrogenase22 leads
to the accumulation of L-glycerate, a reduction product of
hydroxypyruvate made by L-lactate dehydrogenase, and
deﬁciency of D-glycerate kinase23 leads to accumulation of
D-glycerate. These accumulations make sense only if one
considers that the nonphosphorylated pathway serves to
degrade serine.
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